Talis Biomedical Corporation (TLIS) DCF Valuation

Talis Biomedical Corporation (TLIS) DCF Valuation
  • ✓ Fully Editable: Tailor To Your Needs In Excel Or Sheets
  • ✓ Professional Design: Trusted, Industry-Standard Templates
  • ✓ Pre-Built For Quick And Efficient Use
  • ✓ No Expertise Is Needed; Easy To Follow

Talis Biomedical Corporation (TLIS) Bundle

DCF model
Get Full Bundle:
$25 $15
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7

TOTAL:

Whether you’re an investor or analyst, this (TLIS) DCF Calculator is your go-to resource for accurate valuation. Preloaded with Talis Biomedical Corporation's real data, you can adjust forecasts and immediately observe the effects.


Discounted Cash Flow (DCF) - (USD MM)

Year AY1
2019		 AY2
2020		 AY3
2021		 AY4
2022		 AY5
2023		 FY1
2024		 FY2
2025		 FY3
2026		 FY4
2027		 FY5
2028
Revenue 4.0 10.9 .0 3.7 .4 .3 .2 .2 .2 .1
Revenue Growth, % 0 175.03 -100 0 -88.72 -22.18 -22.18 -22.18 -22.18 -22.18
EBITDA -26.0 -90.4 -191.8 -106.3 -66.0 -.2 -.1 -.1 -.1 -.1
EBITDA, % -653.08 -826.67 100 -2910.98 -16030.34 -60 -60 -60 -60 -60
Depreciation .7 1.4 2.6 11.6 .8 .2 .2 .1 .1 .1
Depreciation, % 18.25 12.56 100 317.66 186.89 66.16 66.16 66.16 66.16 66.16
EBIT -26.7 -91.8 -194.4 -117.9 -66.8 -.2 -.1 -.1 -.1 -.1
EBIT, % -671.34 -839.23 100 -3228.64 -16217.23 -60 -60 -60 -60 -60
Total Cash 21.6 138.5 232.5 130.2 76.7 .3 .2 .2 .2 .1
Total Cash, percent .0 .0 .0 .0 .0 .0 .0 .0 .0 .0
Account Receivables 1.8 .5 .2 .3 .1
Account Receivables, % 45.41 4.31 100 8.43 12.14
Inventories .0 46.7 .0 .0 .0 .1 .1 .1 .1 .0
Inventories, % 0 426.62 100 0 0 40 40 40 40 40
Accounts Payable 1.6 4.9 5.1 3.8 1.3 .2 .2 .1 .1 .1
Accounts Payable, % 39.38 44.85 100 103.18 325 76.85 76.85 76.85 76.85 76.85
Capital Expenditure -.6 -8.2 -2.9 -1.6 -.5 -.1 -.1 -.1 -.1 -.1
Capital Expenditure, % -14.53 -74.98 100 -44.22 -117.96 -46.75 -46.75 -46.75 -46.75 -46.75
Tax Rate, % 0 0 0 0 0 0 0 0 0 0
EBITAT -26.7 -91.7 -192.8 -115.7 -66.8 -.2 -.1 -.1 -.1 -.1
Depreciation
Changes in Account Receivables
Changes in Inventories
Changes in Accounts Payable
Capital Expenditure
UFCF -26.8 -140.6 -145.9 -107.2 -68.7 -1.4 -.1 -.1 -.1 .0
WACC, % 5.45 5.46 5.43 5.39 5.46 5.44 5.44 5.44 5.44 5.44
PV UFCF
SUM PV UFCF -1.6
Long Term Growth Rate, % 2.00
Free cash flow (T + 1) 0
Terminal Value -1
Present Terminal Value -1
Enterprise Value -3
Net Debt -57
Equity Value 54
Diluted Shares Outstanding, MM 2
Equity Value Per Share 29.92

What You Will Get

  • Real TLIS Financial Data: Pre-filled with Talis Biomedical Corporation’s historical and projected data for precise analysis.
  • Fully Editable Template: Modify key inputs like revenue growth, WACC, and EBITDA % with ease.
  • Automatic Calculations: See Talis Biomedical Corporation’s intrinsic value update instantly based on your changes.
  • Professional Valuation Tool: Designed for investors, analysts, and consultants seeking accurate DCF results.
  • User-Friendly Design: Simple structure and clear instructions for all experience levels.

Key Features

  • Comprehensive DCF Calculator: Features detailed unlevered and levered DCF valuation models tailored for Talis Biomedical Corporation (TLIS).
  • WACC Calculator: Pre-configured Weighted Average Cost of Capital sheet with adjustable inputs specific to Talis Biomedical Corporation (TLIS).
  • Customizable Forecast Assumptions: Adjust growth rates, capital expenditures, and discount rates to fit your analysis for Talis Biomedical Corporation (TLIS).
  • Integrated Financial Ratios: Evaluate profitability, leverage, and efficiency ratios relevant to Talis Biomedical Corporation (TLIS).
  • Interactive Dashboard and Charts: Visual representations summarize essential valuation metrics for straightforward analysis of Talis Biomedical Corporation (TLIS).

How It Works

  • Step 1: Download the prebuilt Excel template featuring Talis Biomedical Corporation’s (TLIS) data.
  • Step 2: Navigate through the pre-filled sheets to grasp the essential metrics.
  • Step 3: Modify the forecasts and assumptions in the editable yellow cells (WACC, growth, margins).
  • Step 4: Instantly see the recalculated results, including Talis Biomedical Corporation’s intrinsic value.
  • Step 5: Make well-informed investment choices or create reports based on the outputs.

Why Choose This Calculator?

  • Accurate Data: Real Talis Biomedical Corporation (TLIS) financials ensure reliable valuation results.
  • Customizable: Adjust key parameters like growth rates, WACC, and tax rates to match your projections.
  • Time-Saving: Pre-built calculations eliminate the need to start from scratch.
  • Professional-Grade Tool: Designed for investors, analysts, and consultants.
  • User-Friendly: Intuitive layout and step-by-step instructions make it easy for all users.

Who Should Use Talis Biomedical Corporation (TLIS)?

  • Investors: Gain insights into innovative diagnostics and make informed investment choices.
  • Healthcare Professionals: Utilize cutting-edge technology to enhance patient care and diagnostics.
  • Research Analysts: Streamline your analysis with comprehensive data on Talis Biomedical's offerings.
  • Biotechnology Enthusiasts: Explore advancements in molecular diagnostics through real-world applications.
  • Students and Educators: Leverage the company's innovations as case studies in biotechnology and healthcare courses.

What the Template Contains

  • Pre-Filled DCF Model: Talis Biomedical Corporation’s (TLIS) financial data preloaded for immediate use.
  • WACC Calculator: Detailed calculations for Weighted Average Cost of Capital.
  • Financial Ratios: Evaluate Talis Biomedical Corporation’s profitability, leverage, and efficiency.
  • Editable Inputs: Change assumptions such as growth, margins, and CAPEX to fit your scenarios.
  • Financial Statements: Annual and quarterly reports to support detailed analysis.
  • Interactive Dashboard: Easily visualize key valuation metrics and results.

No products were found matching.